Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the intratumoral microbiome and metabolome in pancreatic ductal adenocarcinoma (PDAC), comparing tumor tissue to matched normal adjacent tissue (NAT) from 105 patients.
How was it studied?
Paired tumor and NAT samples underwent 2bRAD-M microbiome sequencing plus untargeted LC-MS and GC-MS metabolomics, with 6 years of survival follow-up.
What did they find?
Microbial diversity was lower in tumors than NAT. Staphylococcus aureus, Cutibacterium acnes, and Cutibacterium granulosum were more abundant in tumors after adjusting for BMI and metastasis stage. Tumors carrying Ralstonia pickettii had significantly worse overall survival, 17 months versus 37 months (hazard ratio 2.79). Metabolomics identified 553 discriminative metabolites, many microbiota-linked, correlating with shifts in glycerol-3-phosphate, succinate, carbonate, and beta-alanine.
Why it matters
The findings suggest specific tumor-resident bacteria and their metabolic byproducts may influence PDAC development and prognosis, pointing toward possible microbiome-targeted therapeutic strategies.